For research use only. Not for therapeutic Use.
NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson’s disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome[1][2][3].
NNZ 2591 (30 mg/kg; p.o.) prevented scopolamine-induced memory impairment in rats[1].
NNZ 2591 (2, 20, 100 ng/rat; i.c.v.) shows neuroprotection in rats[2].
NNZ 2591 (3 mg/kg; s.c.; daily for 5 days) completely preventes brain damage and significantly reduces the L/R ratio of time taken to touch to the patch at 5 d after injury in rats[2].
| Catalog Number | I042645 |
| CAS Number | 847952-38-9 |
| Synonyms | (8aR)-8a-prop-2-enyl-3,6,7,8-tetrahydro-2H-pyrrolo[1,2-a]pyrazine-1,4-dione |
| Molecular Formula | C10H14N2O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C10H14N2O2/c1-2-4-10-5-3-6-12(10)8(13)7-11-9(10)14/h2H,1,3-7H2,(H,11,14)/t10-/m0/s1 |
| InChIKey | WVKCGUOWPZAROG-JTQLQIEISA-N |
| SMILES | C=CCC12CCCN1C(=O)CNC2=O |
| Reference | [1]. Guan J, et al. NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behav Brain Res. 2010 Jul 11;210(2):221-8. [2]. Guan J, et al. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Neuropharmacology. 2007 Nov;53(6):749-62. [3]. Copping NA, et al. Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome. Neurotherapeutics. 2021 Jul;18(3):1535-1547. |
